![CEPI Extends Partnership With Clover Biopharmaceuticals to Fund COVID-19 Vaccine Candidate Through Global Phase 2/3 Study to Licensure | Business Wire CEPI Extends Partnership With Clover Biopharmaceuticals to Fund COVID-19 Vaccine Candidate Through Global Phase 2/3 Study to Licensure | Business Wire](https://mms.businesswire.com/media/20201102005858/en/787489/23/Logos.jpg)
CEPI Extends Partnership With Clover Biopharmaceuticals to Fund COVID-19 Vaccine Candidate Through Global Phase 2/3 Study to Licensure | Business Wire
![Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest](https://mma.prnewswire.com/media/1631952/Clover_X_CEPI_Logo.jpg?p=facebook)
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
![Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System | Business Wire Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System | Business Wire](https://mms.businesswire.com/media/20200224005319/en/775182/23/Clover-GSK_Logos.jpg)
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System | Business Wire
![CEPI to fund development of Clover's S-Trimer COVID-19 vaccine through phase 2/3, licensure - Homeland Preparedness News CEPI to fund development of Clover's S-Trimer COVID-19 vaccine through phase 2/3, licensure - Homeland Preparedness News](https://homelandprepnews.com/wp-content/uploads/2020/10/shutterstock_1673662414-1.jpg)
CEPI to fund development of Clover's S-Trimer COVID-19 vaccine through phase 2/3, licensure - Homeland Preparedness News
![CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure | CEPI CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure | CEPI](https://static.cepi.net/images/3840x2160/2024-01/IMAGE-CLOVER-EXPANDED-PARTNERSHIP.webp)
CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure | CEPI
![Starter ručni poteznica trimeri Clover CG330 ,Farmer PRO 520,Iskra,Flora best, Villager BC900 | Permoto d.o.o. Starter ručni poteznica trimeri Clover CG330 ,Farmer PRO 520,Iskra,Flora best, Villager BC900 | Permoto d.o.o.](https://www.permoto.hr/wp-content/uploads/2016/09/Starter-Ru%C4%8Dni-Poteznica-Trimeri-Clover-CG330-Farmer-PRO-520IskraFlora-Best-Villager-BC900.jpg)
Starter ručni poteznica trimeri Clover CG330 ,Farmer PRO 520,Iskra,Flora best, Villager BC900 | Permoto d.o.o.
![Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate](https://mma.prnewswire.com/media/1430155/CLOVER_DYNAVAX_Logo.jpg?p=facebook)